https://www.selleckchem.com/products/tak-779.html
ike illness caused by any strain of 8·8% (-16·7 to 28·7). 263 (4·1%) of 6352 participants in the QVLP group versus 266 (4·2%) of 6366 in the QIV group had serious adverse events (one [0·1%] vs two [0·1%] were considered treatment-related); one (0·1%) versus three (0·1%) participants had severe treatment-related treatment-emergent adverse events. These efficacy studies are the first large-scale studies of any plant-derived human vaccine. Together, they show that the plant-derived QVLP vaccine can provide substantial prote
Like
Comment
Share
